Fradafiban (BIBU-52) |
| Katalog-Nr.GC32562 |
Fradafiban (BIBU-52) ist ein nichtpeptidischer Thrombozyten-Glykoprotein-IIb/IIIa-Antagonist, der mit einem Kd-Wert von 148 nM an den humanen Thrombozyten-GP IIb/IIIa-Komplex bindet.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 148396-36-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Fradafiban is a nonpeptide platelet glycoprotein IIb/IIIa antagonist, which binds to the human platelet GP IIb/IIIa complex with a Kd value of 148 nM.
Fradafiban is a nonpeptide mimetic of the arginine-glycine-aspartic acid recognition sequence. Fradafiban binds with high affinity and selectivity to the human platelet GP IIb/IIIa complex and potently inhibits human platelet aggregation in vitro. Fradafiban reversibly binds to the human platelet GP IIb/IIIa complex with a Kd value of 148 nM[1].
Fradafiban has only very limited oral activity probably due to its high polarity and thus poor absorption after oral ingestion[1].
[1]. Müller TH, et al. Profound and sustained inhibition of platelet aggregation by Fradafiban, a nonpeptide platelet glycoprotein IIb/IIIa antagonist, and its orally active prodrug, Lefradafiban, in men. Circulation. 1997 Aug 19;96(4):1130-8.
Average Rating: 5 (Based on Reviews and 12 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *